AF
VIVO

Amalgamated Financial’s Meridian Bioscience Inc VIVO Stock Holding History

Amalgamated Financial’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$509K Buy
+19,589
New +$466K ﹤0.01% 1508

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's VIVO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Meridian Bioscience Inc (VIVO) in Q1 2022: 19,589 shares worth $509K. The stake represents ﹤0.01% of the portfolio and ranks #1508 among its holdings.

210 funds tracked by Wall St. Rank hold VIVO as of Q1 2022.

  • Amalgamated Financial held 19,589 shares of Meridian Bioscience Inc worth $509K as of Q1 2022.
  • Meridian Bioscience Inc was a new Amalgamated Financial position in Q1 2022.
  • Meridian Bioscience Inc made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1508 holding.
  • 210 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.